Portfolio news 0

Storm Therapeutics

STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications

Pulmocide

Pulmocide announces termination of Opera-T Phase 3 study with Opelconazole

Oxford Quantum Circuits Limited

OQC Appoints Darko Stojkovic as Chief Operating Officer to Strengthen Global Leadership and Operational Scale-Up

Iksuda Therapeutics Ltd

Iksuda to present preliminary analysis of oesophageal cancer data from Phase 1 study of IKS014 at ASCO Gastrointestinal Cancer Symposium

Centessa Pharmaceuticals plc

Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications

Quantum Motion Technologies

Quantum Motion Scientist and Professor M. Fernando Gonzalez Zalba Awarded Competitive ERC Consolidator Grant

Enterprise Therapeutics

Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis

First Light Fusion Ltd

First Light Fusion Awarded Key Contract to Help Advance UK Fusion Energy

Quantum Dice

EIC Accelerator backs Quantum Dice with €2m grant to advance probabilistic computing

Oxford Nanopore Technologies Plc

Oxford Nanopore Technologies Plc - Appointment of Francis Van Parys as Chief Executive Officer